Cargando…

Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma

This phase I study evaluated the safety and efficacy of single-agent ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (aged 20-69 years and ineligible for chemotherapy using fludarabine or cyclophosphamide, or aged ≥70 years). Eight pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shibayama, Hirohiko, Teshima, Takanori, Choi, Ilseung, Hatake, Kiyohiko, Sekiguchi, Naohiro, Yoshinari, Nozomi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JSLRT 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954169/ https://www.ncbi.nlm.nih.gov/pubmed/31866619 http://dx.doi.org/10.3960/jslrt.19023

Ejemplares similares

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Ogura, Michinori, et al.
Publicado: (2013)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib
por: Koshiishi, Megumi, et al.
Publicado: (2021)

Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: McNally, Gretchen Anne, et al.
Publicado: (2015)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib
por: Koba, Yusuke, et al.
Publicado: (2023)

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
por: Fraser, G., et al.
Publicado: (2018)

Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study
por: Huang, Xiaojun, et al.
Publicado: (2018)

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
por: Hillmen, Peter, et al.
Publicado: (2023)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
por: Tucker, David L, et al.
Publicado: (2015)

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
por: Kidoguchi, Keisuke, et al.
Publicado: (2021)

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study
por: Ohmachi, Ken, et al.
Publicado: (2018)

Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
por: Molica, Stefano, et al.
Publicado: (2016)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
por: Arthurs, Benjamin, et al.
Publicado: (2017)

Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib
por: Sittig, Katherine R., et al.
Publicado: (2021)

Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
por: Liu, Yanyan, et al.
Publicado: (2022)

Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
por: Mahlich, Jörg, et al.
Publicado: (2017)

Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Lee, Philip, et al.
Publicado: (2022)

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study
por: Woyach, Jennifer A., et al.
Publicado: (2023)

Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies
por: Robak, Tadeusz, et al.
Publicado: (2018)

Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
por: Fraser, Graeme A.M., et al.
Publicado: (2020)

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
por: Okamoto, Koh, et al.
Publicado: (2016)

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
por: Landau, Dan A., et al.
Publicado: (2017)

Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy
por: Voshtina, Ensi, et al.
Publicado: (2018)

Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia
por: Beresford, Rohan, et al.
Publicado: (2019)

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
por: Fiorcari, Stefania, et al.
Publicado: (2016)

Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia
por: Lutz, Mathias, et al.
Publicado: (2017)

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
por: Zhou, Hong, et al.
Publicado: (2020)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
por: Hampel, Paul J., et al.
Publicado: (2022)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
por: Munir, Talha, et al.
Publicado: (2019)

Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
por: Kato, Koji, et al.
Publicado: (2021)

Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients
por: Boissard, F, et al.
Publicado: (2015)

COVID-19 IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN USE OF IBRUTINIB: NOT THAT RISKY?
por: Dourado, M.L.B.F., et al.
Publicado: (2020)

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy
por: Al‐Katib, Ayad M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ho1skjim2cbtutuuk556h3c26l